Is Becton, Dickinson & Co. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Becton, Dickinson & Co. moved from very expensive to expensive, indicating a shift towards a less favorable valuation. The company appears overvalued based on its current metrics, with a P/E ratio of 33, a Price to Book Value of 2.52, and an EV to EBITDA of 16.57. In comparison to peers, Abbott Laboratories has a more attractive P/E of 18.36, while Thermo Fisher Scientific, Inc. shows a lower EV to EBITDA of 21.65, suggesting that Becton, Dickinson & Co. is trading at a premium relative to these competitors.
Furthermore, the company's stock has significantly underperformed against the S&P 500, with a year-to-date return of -21.23% compared to the index's 16.30%. This underperformance reinforces the notion that Becton, Dickinson & Co. is overvalued in the current market context.